AKT1 and acute myeloid leukemia: Indeed, in primary AML cells, CD157 stimulation by antibody binding activated the PI3K/AKT/mTOR and MAPK/ERK pathways, while inactivating GSK3-β kinase thus leading to extended ex vivo survival and reduced sensitivity to AraC treatment.